In this community call, the new co-chair team (Mary O’Reilly, Maaike Everts, Raeka Aiyar) facilitated an open discussion to reboot the Therapeutic Development (formerly known as Drugs and Other Therapy... read more →
We held a one hour session where Mark Roithmayr, CEO Alzheimer’s Drug Discovery Foundation (a pure Venture Philanthropy nonprofit), interviewed John Walter, CEO Food Allergy Science Initiative, who has helped... read more →
Building on past presentations where we spotlighted the individual efforts of the Leukemia & Lymphoma Society, Foundation Fighting Blindness, and JDRF, in another of our Venture Philanthropy series we heard... read more →
The Flinn Foundation launched the bioscience Entrepreneurship Program in 2014 to foster entrepreneurship and help bioscience founders/CEOs develop their early-stage companies into successful and sustainable businesses bringing new therapies, medical... read more →
In November 2016, HRA sponsored a workshop at the FDA entitled “Gene Editing: FDA-Regulated Technologies and Applications.” The keynote speaker was Jennifer Doudna and her talk was titled “CRISPR-Cas Genome... read more →
Venture philanthropy does not come without its fair share of controversy. It remains a challenge for nonprofits, philanthropists, patients, start-ups and the general public to determine how – and if... read more →
The open access protocols.io platform makes it easy to share research recipes and to collaborate on method development, both publicly and privately. This free platform addresses lack of reproducibility due to less than... read more →
Institutional Review Boards (IRBs) play a hidden but critical role in the common project to advance knowledge and improve life experience. They ensure that the imperatives of science are balanced... read more →
The inaugural Tri-State Regional Meeting (co-hosted by NYSCF and the Doris Duke Charitable Foundation) was held in the NYSCF’s office January 31, 2018. With over 15 member organization represented, this... read more →
The cost of drug R&D makes up the bulk of the cost of prescription drugs because consumers not only pay for the medicines they are prescribed, but also for all... read more →